Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Completed · Phase 4

Conditions studied: Glaucoma

In brief

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Key facts

Study ID

NCT00348023

Run by

Innovative Medical

Last updated by the study team

2007-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• · Male or female > 18 years of age
• Diagnosis of primary open-angle glaucoma or ocular hypertension
• Untreated IOP > 18 mm Hg in each eye at the baseline evaluation
• Ability to provide informed consent and likely to complete all study visits

You may not qualify if…

• · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication
• Uncontrolled systemic disease
• Active ocular disease other than POAG or ocular hypertension
• Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)
• History of intraocular surgery within the last 3 months
• Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance

Where it is running

• Dr. Noecker — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.